About
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel,...
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
  • 14
    Oct
    19
    News Release
    Immunicum AB (publ) Announces Nomination Committee for AGM 2020
  • 9
    Oct
    19
    Equity Research
    Immunicum AB (OMX:IMMU) Research Update
  • 1
    Oct
    19
    News Release
    Immunicum AB (publ) Announces Advancement to Next Dosage Group Level in Phase Ib/II ILIAD Combination Trial
  • 25
    Sep
    19
    Company Presentation
    Complete Topline Data Analysis from Phase II MERECA Trial
  • 25
    Sep
    19
    News Release
    Immunicum AB (publ) Announces Complete Topline Data Analysis from Phase II MERECA Trial
  • 4
    Sep
    19
    Corporate Update
    Video Interviews on MERECA Phase II Data
  • 30
    Aug
    19
    Corporate Update
    MERECA Q&A
  • 29
    Aug
    19
    News Release
    Information on MERECA
  • 29
    Aug
    19
    News Release
    Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients
  • 20
    Aug
    19
    News Release
    Immunicum AB (publ) Interim Report January – June 2019
  • 20
    Aug
    19
    Company Presentation
    Quarterly Report Presentation & Business Strategy slides
  • 11
    Jul
    19
    Equity Research
    Immunicum AB (OMX:IMMU) Research Initiation
  • 28
    Jun
    19
    News Release
    Immunicum AB (publ) Announces New Issuance Date for Interim Report April – June 2019 and Corporate Update Event
  • 12
    Jun
    19
    News Release
    Immunicum AB (publ) Announces Positive Topline Results from the Phase I/II Clinical Trial in GIST
  • 29
    May
    19
    Corporate Update
    Radiumhemmets Forskningsfonder Article (Swedish Only)
  • 28
    May
    19
    News Release
    Immunicum AB (publ) Announces Outcome of Subscription in Employee Incentive Program 2019/2022
  • 22
    May
    19
    Company Presentation
    Corporate presentation May 2019
  • 7
    May
    19
    News Release
    Immunicum AB (publ) Announces Upcoming Conferences in May and June
  • 29
    Apr
    19
    Corporate Update
    Immunicums ilixadencel ger nytt hopp till cancerpatienter
  • 25
    Apr
    19
    News Release
    Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019
  • 25
    Apr
    19
    News Release
    Immunicum AB (publ) Interim Report January – March 2019
  • 25
    Apr
    19
    Company Presentation
    Immunicum Presentation April 2019
  • 25
    Apr
    19
    Corporate Update
    Interim Report 2019 January-March
  • 4
    Apr
    19
    News Release
    Immunicum AB (publ) Publishes the Annual Report for 2018
  • 3
    Apr
    19
    Corporate Update
    Annual Report 2018
  • 26
    Mar
    19
    News Release
    Notice of Annual General Meeting in Immunicum AB (publ)
  • 21
    Feb
    19
    Company Presentation
    Investor Presentation February 2019
  • 15
    Feb
    19
    News Release
    Year-end report 2018
  • 15
    Feb
    19
    News Release
    Immunicum AB (publ) Year-End Report 2018
  • 11
    Feb
    19
    News Release
    Immunicum AB (publ) Announces First Patient Treated in Phase Ib/II ILIAD Combination Trial
  • 31
    Jan
    19
    News Release
    Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue
  • 30
    Jan
    19
    News Release
    Changes to the Nomination Committee for Immunicum AB (publ)
  • 21
    Jan
    19
    News Release
    Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology
  • 28
    Dec
    18
    News Release
    Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue
  • 13
    Dec
    18
    News Release
    Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M
  • 8
    Nov
    18
    News Release
    Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018
  • 7
    Nov
    18
    News Release
    Interim report Jan - Sept 2018
  • 7
    Nov
    18
    Company Presentation
    Company Presentation November 2018
  • 7
    Nov
    18
    News Release
    Immunicum AB (publ) Interim Report July – September 2018
  • 22
    Oct
    18
    News Release
    Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018
  • 19
    Oct
    18
    News Release
    Immunicum AB (publ) Announces Nomination Committee for AGM 2019
  • 1
    Oct
    18
    News Release
    Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration
  • 17
    Sep
    18
    News Release
    Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board
  • 17
    Aug
    18
    News Release
    Interim report Jan - June 2018
  • 17
    Aug
    18
    News Release
    Immunicum AB (publ) Interim Report April – June 2018
  • 13
    Aug
    18
    News Release
    Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress
  • 23
    Jul
    18
    News Release
    Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial
  • 18
    Jun
    18
    News Release
    Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research
  • 21
    May
    18
    News Release
    Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial
  • 4
    May
    18
    News Release
    Interim report Jan - March 2018
  • 4
    May
    18
    News Release
    Immunicum AB (publ) Interim report January – March 2018
  • 3
    Apr
    18
    News Release
    Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program
  • 20
    Mar
    18
    News Release
    Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data
  • 14
    Mar
    18
    News Release
    The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board